BIOSPAIN 2026: Full Schedule

10:15 CEST

Inside Spanish Biotech VC Playbooks: What Moves the Investment Needle

Tuesday September 29, 2026 10:15 - 11:00 CEST

Want to tilt the odds in your favor on the roadshow? Hear it straight from the source: Spain’s top biotech VCs will unveil their investment playbooks—how they judge scientific risk, vet team credentials and experience, assess development plans, and prioritise therapeutic areas. Each investor gets a brisk, 9-minute spotlight to explain what truly moves the needle. Walk away with a sharper sense of how opportunities are valued and what to emphasize in your pitch.

Moderators

Guillermo Serrano

PartNer, Checkpoint Partners

Speakers

Arturo Urrios

Partner, Ysios Capital

Arturo leads early-stage investments and company creation at Ysios Capital, driving the firm’s early-stage initiative.Previously, he worked at M Ventures and most recently at Wellington Parties, where he was involved in multiple financings including Riffyn (acquired by Siemens... Read More →

Tracy Weightman

Montana Children's Health Venture Fund

Laura Rodríguez Gallego

Partner, Invivo Partners

Clara Campás

Managing partner and co-founder of Asabys, Asabys Partners

Managing partner and co-founder of Asabys. Clara currently serves on the board of directors of Ona Therapeutics, Nuage Therapeutics, ALLOX and Augustine Therapeutics.Formerly, Clara served as Strategy & Development Director at Kern Pharma and held several positions at Advancell, including... Read More →

María Poveda

Director Alternative Assets I Life Sciences, Inveready

María joined Inveready in 2018, she is responsible of identifying investment opportunities and leading the investment process. She has actively contributed to the construction of Inveready Biotech III’s portfolio. Furthermore, she provides support and monitors the performance of... Read More →

Tuesday September 29, 2026 10:15 - 11:00 CEST
4 Raúl Martín room

Reverse pitch presentation

Audience English language
Subject AseBio Proposal
Track Finance & investment

BIOSPAIN 2026